SNT.AX Syntara Limited pre-market 04 Feb 2026: Feb 6 earnings will test clinical progress

SNT.AX stock trades at A$0.035 as we head into the pre-market session on 04 Feb 2026, with an earnings announcement scheduled for 06 Feb 2026. The price jumped +9.38% on recent data to A$0.035 on volume 1,901,127.00, signalling investor attention ahead of clinical and financial updates. Syntara Limited (ASX: SNT.AX) is a clinical-stage healthcare developer; upcoming commentary on trial progress for amsulostat may drive near-term volatility and re-rating opportunities.

SNT.AX stock: Earnings preview and what to watch

Earnings for SNT.AX are due on 06 Feb 2026 and investors will focus on cash runway, R&D milestone spend and any update on Phase 1c/2 amsulostat data. The company has EPS -0.01 and a reported PE -3.00, reflecting negative earnings typical for clinical-stage biotech. Expect management commentary on trial enrolment, cash guidance and potential partnering timelines that can materially affect sentiment.

SNT.AX stock technicals and recent price action

SNT.AX last traded A$0.035 with a day low of A$0.031 and day high of A$0.036, and year range A$0.023–A$0.095. Volume of 1,901,127.00 compares with an average volume of 1,312,920.00, showing higher-than-normal trading interest ahead of earnings. The 50-day average is A$0.03224 and the 200-day average is A$0.04126, suggesting the stock is between short- and medium-term technical support and resistance.

SNT.AX stock financials and valuation metrics

Market capitalisation is A$48,971,976.00 with 1,632,399,195.00 shares outstanding. Key balance metrics include cash per share A$0.01, book value per share A$0.01, and a current ratio 3.93, indicating liquidity to fund near-term R&D. Price-to-book is 2.75 and free cash flow yield is negative, reflecting investment-phase spending. These ratios align with a clinical-stage profile where clinical outcomes, not revenues, drive value.

Pipeline catalysts: clinical milestones that may move SNT.AX stock

Syntara’s lead candidate amsulostat targets myelofibrosis and is in Phase 1c/2; topical pan-LOX programs (SNT-9465, SNT-6302) are in early human studies. Clinical readouts, safety updates or partnership announcements could trigger sizable moves given the small market cap and thin float. Conversely, delayed enrolment, negative safety signals or a cash warning would likely pressure the stock, reflecting typical biotech binary risk.

Meyka AI rate, consensus signals and SNT.AX stock forecast

Meyka AI rates SNT.AX with a score out of 100: 58.85 — Grade C+ (HOLD). This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics and analyst consensus. Company-specific ratings show a broader firm score of C with a recommendation of Sell from alternate rating models dated 02 Feb 2026. Meyka AI’s forecast model projects monthly A$0.04 and quarterly A$0.04, implying an upside of 14.29% from the current A$0.035. Forecasts are model-based projections and not guarantees.

Risks, sector context and trading considerations for SNT.AX stock

Syntara sits in the ASX Healthcare sector where peers trade at an average PE 33.69 and average PB 5.70; SNT.AX metrics are structurally different due to its clinical-stage status. Major risks include negative trial outcomes, dilution from capital raises and low liquidity that can amplify moves. Traders should expect elevated volatility around the Feb 6 earnings and weigh position size accordingly. For long-term investors, clinical outcome probabilities and cash runway will determine re-rating potential.

Final Thoughts

Key takeaways for SNT.AX stock ahead of the Feb 6 earnings: Syntara is a small clinical-stage healthcare company trading at A$0.035 with EPS -0.01 and market cap A$48,971,976.00. The upcoming report is likely to focus on trial progress for amsulostat, R&D spending and cash position. Our median model projects A$0.04 over the near term, an implied upside of 14.29% versus the current price, but that projection is model-based and not a guarantee. Meyka AI’s grade of C+ (58.85/100) reflects mixed signals: strong liquidity metrics versus negative profitability and high binary clinical risk. Institutional or risk-tolerant investors should prioritise the company’s cash runway and clinical readouts. Short-term traders may see news-driven moves; long-term investors should await clearer efficacy or partnership signals before increasing exposure. For company filings and regulatory updates, see Syntara’s website and ASX announcements. For in-depth live data, check our Meyka AI stock page for SNT.AX.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.